A5102923763- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Meningioma and schwannoma management
- Bone Tumor Diagnosis and Treatments
- Sarcoma Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Pituitary Gland Disorders and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Ocular Oncology and Treatments
- Oral and Maxillofacial Pathology
- Radiomics and Machine Learning in Medical Imaging
- Head and Neck Surgical Oncology
- Adrenal and Paraganglionic Tumors
- Radiation Therapy and Dosimetry
- Lymphoma Diagnosis and Treatment
- Management of metastatic bone disease
- Vascular Malformations Diagnosis and Treatment
- Cancer-related cognitive impairment studies
- Lung Cancer Research Studies
- Prostate Cancer Treatment and Research
- Salivary Gland Tumors Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Neurofibromatosis and Schwannoma Cases
- Vascular Tumors and Angiosarcomas
- Ear and Head Tumors
Hospices Civils de Lyon
2022-2025
Hôpital Pierre Wertheimer
2025
Sorbonne Université
2015-2024
Pitié-Salpêtrière Hospital
2015-2024
Assistance Publique – Hôpitaux de Paris
2015-2024
Institut Curie
2010-2023
Hôpital Charles-Foix
2018-2023
Hôpital Lyon Sud
2023
Proton (Malaysia)
2022
Sorbonne Paris Cité
2020
Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy added standard radiotherapy (60 Gy over period 6 weeks). In elderly patients, more convenient shorter courses are commonly used, but benefit adding course unknown.We conducted trial involving 65 older newly diagnosed glioblastoma. Patients were randomly assigned receive either alone (40 15 fractions) concomitant and...
To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy autologous stem-cell transplantation (ASCT) as a first-line treatment primary CNS lymphoma (PCNSL).Immunocompetent patients (18 to 60 years age) with untreated PCNSL were randomly assigned receive WBRT ASCT consolidation after induction consisting two cycles R-MBVP (rituximab 375 mg/m2 day (D) 1, methotrexate 3 g/m2 D1; D15, VP16 100 D2, BCNU D3,...
Real-life studies on patients with primary CNS lymphoma (PCNSL) are scarce. Our objective was to analyze, in a nationwide population-based study, the current medical practice management of PCNSL.The French oculo-cerebral network (LOC) database prospectively records all newly diagnosed PCNSL cases from 32 centers. Data between 2011 and 2016 were retrospectively analyzed.We identified 1,002 immunocompetent (43% aged >70 years, median Karnofsky Performance Status [KPS] 60). First-line treatment...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.We previously reported of a randomized phase II study patients with newly diagnosed CNS lymphoma (age 18-60 years)....
Histiocytic sarcoma (HS) is classified within the malignant histiocytic disorders.1 Involvement of isolated CNS in HS, termed primary CNS-HS (PCNS-HS), characterized by a proliferation cells monocyte/macrophage lineage CNS.2–6 This case report documents clinical, biological, pathologic, and radiologic spectrums PCNS-HS. Acknowledgment: The authors thank Groupe Français d'Etude des Histiocytoses Dr. Frederic Charlotte for help with pathologic review.
Chordomas are slow-growing malignant neoplasms. Determination of histopathologic prognostic factors using a large cohort study has been limited by their low incidence. In this retrospective study, we investigated the clinical, histopathologic, and immunohistochemical in 287 chordomas from 111 patients assessed central pathologic review. Expression patterns variety markers, including vascular endothelial growth factor (VEGF), mTOR pathway, c-kit, HER2, epidermal receptor (EGFR) STAT3, KRAS,...
2008 Background: For non-small cell lung cancer (NSCLC) with brain metastases (BM) stereotactic radiosurgery (SRS) is the current preferred therapy. Due to frequent intracranial failures, there a high unmet need for salvage therapies. Whole radiotherapy (WBRT) reduces failure but used less frequently due cognitive consequences. Tumor Treating Fields (TTFields) are electric fields that disrupt division and have shown improved survival safety in patients glioblastoma metastatic NSCLC. Phase 3...
Abstract Objective Targeted therapy (TT) with BRAF/MEK inhibitors has emerged as a potential treatment in papillary craniopharyngiomas (PCPs). However, standardized data on large cohorts are lacking. Our study aimed to assess real-life efficacy and safety of inhibition patients PCPs. Design Retrospective French multicenter involving BRAF V600E–mutated PCP patients, treated inhibitor combination dabrafenib trametinib, from April 2019 July 2023. Methods response clinical outcomes were assessed...
Abstract Background Aggressive pituitary tumors and carcinomas represent very uncommon entities within the field of diseases. Unfortunately, treatment options after progression on temozolomide are limited. However, advances in understanding tumor genetics their immunological landscape paving way for new targeted molecular therapies. Methods In this article, we present an overview most recent literature, focusing specificities role current treatments future perspectives management these...
Abstract Background: Radio-chemotherapy remains the mainstay of glioblastoma first-line treatment after extended surgery, but prognosis is still poor. PARP inhibitors like olaparib may improve outcomes. We implemented a phase 1-2a trial to assess safety and efficacy combined with standard radio-chemotherapy as in unresected patients. herein present results 1. Methods: Based on Stupp regimen, two sequential dose escalations were performed distinguish radiotherapy period maintenance for...
<p>A. Progression-free (left) and overall (right) survival among the 30 patients enrolled in two sequential olaparib dose-escalations of trial.</p>
<p>C. Progression-free (left) and overall (right) survival for first second olaparib dose-escalation cohorts of the trial. was defined as time elapsed from treatment start to RANO progression or death any cause (whichever occurs first); Overall cause.</p>
<p>B. Progression-free (left) and overall (right) survival according to MGMT status among the patients enrolled in two sequential olaparib dose-escalations of trial.</p>
<p>Magnetic Resonance Imaging (gadolinium, FLAIR and perfusion sequences from left to right) at baseline (top) 60 months (bottom) after start of treatment in first line a partially resected glioblastoma patient.</p>
<div>AbstractPurpose:<p>Radiochemotherapy remains the mainstay of glioblastoma (GBM) first-line treatment after extended surgery, but prognosis is still poor. PARP inhibitors like olaparib may improve GBM outcomes. We implemented a phase I to IIa trial assess safety and efficacy combined with standard radiochemotherapy as in patients unresected GBM. herein present results I.</p>Patients Methods:<p>Based on Stupp regimen, two sequential dose escalations were performed...